Table 1 Baseline features of the study patients
Variable (n of patients with available data) | All patients (n = 708) | Probablea CAPA (n = 18) | No CAPAa (n = 690) | Univariate HR (95% CI) | P value |
|---|---|---|---|---|---|
Demographics, mean ± SD or n (%) | |||||
Age (n = 708) | 65 ± 11 | 70 ± 7 | 65 ± 11 | 1.04 (1.00–1.09) | 0.04 |
Male (n = 708) | 522 (73.7) | 15 (83.3) | 507 (73.5) | 1.56 (0.45–5.38) | 0.48 |
BMI (kg/m2) (n = 704) | 30 ± 6 | 28 ± 5 | 30 ± 6 | 0.95 (0.87–1.03) | 0.20 |
Severity scores, mean ± SD | |||||
SAPS II (n = 642) | 39 ± 13 | 39 ± 13 | 39 ± 13 | 0.99 (0.96–1.03) | 0.69 |
SOFA score (n = 626) | 5 ± 3 | 4 ± 2 | 5 ± 3 | 0.88 (0.76–1.02) | 0.09 |
Comorbidities, mean ± SD or n (%) | |||||
Charlson’s Comorbidity Index (n = 703) | 4 ± 3 | 5 ± 3 | 4 ± 3 | 1.07 (0.92–1.24) | 0.41 |
Diabetes (n = 708) | 222 (31.4) | 3 (16.7) | 219 (31.7) | 0.42 (0.12–1.40) | 0.16 |
Hypertension (n = 708) | 387 (54.7) | 10 (55.6) | 377 (54.6) | 0.99 (0.39–2.51) | 0.98 |
Chronic respiratory failure (n = 708) | 138 (19.5) | 5 (27.8) | 133 (19.3) | 1.49 (0.53–4.17) | 0.45 |
Chronic heart failure (n = 708) | 111 (15.7) | 3 (16.7) | 108 (15.7) | 1.03 (0.30–3.50) | 0.96 |
Chronic kidney failure (n = 708) | 68 (9.6) | 1 (5.6) | 67 (9.7) | 0.48 (0.07–3.49) | 0.47 |
Cirrhosis (n = 708) | 40 (5.7) | 2 (11.1) | 38 (5.5) | 1.91 (0.43–8.51) | 0.40 |
Any immunosuppression (n = 708) | 113 (16) | 4 (22.2) | 109 (15.8) | 1.32 (0.42–4.09) | 0.63 |
Solid organ transplantation (n = 708) | 18 (2.5) | 0 (0.0) | 18 (2.6) | NA | NA |
Active hematological or solid malignancy (n = 708) | 58 (8.2) | 3 (16.7) | 55 (8) | 1.81 (0.50–6.50) | 0.36 |
HIV (n = 708) | 7 (1) | 1 (5.6) | 6 (0.9) | 7.51 (0.88–64.0) | 0.07 |
Immunosuppressive drugs (n = 708) | 35 (4.9) | 1 (5.6) | 34 (4.9) | 1.15 (0.16–8.56) | 0.89 |
Treatments for COVID-19, n (%) | |||||
Corticosteroids (n = 707) | 446 (63.1) | 12 (66.7) | 434 (63) | 1.08 (0.39–3.01) | 0.88 |
IL6 antagonist (n = 699) | 4 (0.6) | 0 (0.0) | 4 (0.6) | NA | NA |
Hydroxychloroquine (n = 708) | 92 (13) | 2 (11.1) | 90 (13) | 0.88 (0.20–3.81) | 0.87 |
Lopinavir/rotinavir (n = 708) | 88 (12.4) | 4 (22.2) | 84 (12.2) | 1.79 (0.62–5.20) | 0.28 |
Remdesivir (n = 708) | 26 (3.7) | 0 (0.0) | 26 (3.8) | NA | NA |